| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Lung and Thoracic cancer
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
Yu Feng, Yutao Liu, Mingming Yuan, Guilan Dong, Hongxia Zhang, Tongmei Zhang, Lianpeng Chang, Xuefeng Xia, Lifeng Li, Haohua Zhu, Puyuan Xing, Hongyu Wang, Yuankai Shi, Zhijie Wang, Xingsheng Hu
Cancer Res Treat. 2022;54(3):753-766.   Published online October 5, 2021    DOI: https://doi.org/10.4143/crt.2021.905
                              Supplementary         Cited By 1
Hematologic malignancy
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
Sang Eun Yoon, Yeon Jeong Kim, Joon Ho Shim, Donghyun Park, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Yeung-Chul Mun, Kyoung Eun Lee, Duck Cho, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2022;54(2):597-612.   Published online July 23, 2021    DOI: https://doi.org/10.4143/crt.2021.752
                              Supplementary         Cited By 1
Lung cancer
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat. 2021;53(1):93-103.   Published online September 21, 2020    DOI: https://doi.org/10.4143/crt.2020.459
                              Supplementary         Cited By 1
Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer
Mi-Ryung Han, Sug Hyung Lee, Jung Yoon Park, Hyosun Hong, Jung Yoon Ho, Soo Young Hur, Youn Jin Choi
Cancer Res Treat. 2020;52(3):779-788.   Published online February 28, 2020    DOI: https://doi.org/10.4143/crt.2019.700
                              Supplementary         Cited By 11
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat. 2019;51(2):777-787.   Published online September 7, 2018    DOI: https://doi.org/10.4143/crt.2018.387
                              Supplementary         Cited By 24
Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
Seok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, Kyung Ju Ryu, Bon Park, Donghyun Park, Duck Cho, Hyun-Young Kim, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Won Seog Kim
Received January 11, 2022   Accepted February 23, 2022   Published online March 2, 2022
DOI: https://doi.org/10.4143/crt.2022.017    
[Epub ahead of print]
                              Supplementary      
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI